Shots:
- Biohaven has granted SK Biopharmaceuticals exclusive worldwide rights to its Kv7 ion channel platform, led by opakalim (BHV-7000), a P-II/III candidate for focal epilepsy, with RISE3 topline results are expected in H2’26
- Biohaven will receive upfront & milestone payments up to $795M for the Kv7 platform, incl. $400M in cash ($350M at closing & $50M in 2027), ~$150M in development/regulatory milestones, & tiered royalties from the mid-teens to low twenties on US opakalim sales plus mid-single-digit royalty on ex-US sales
- SK Biopharmaceuticals will assume future Kv7 program costs, incl. ~$185M payable to Knopp upon US and EU approval, a separate mid-single-digit global royalty, as well as ~$60M in future Kv7 pipeline milestones
Ref: PRnewswire | Image: Biohaven & SK Biopharmaceuticals | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
